ECM
PRDS

ExodusPoint Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

ExodusPoint Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-49,699
Closed -$359K – 2632
2022
Q1 		$359K Buy
+49,699
New +$489K ﹤0.01% 1696

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ExodusPoint Capital Management's PRDS Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2022, closing a stake of 49,699 shares — an estimated $359K sold.

ExodusPoint Capital Management first reported a position in PRDS in Q1 2022 and held it in 1 quarter. The position peaked at $359K in Q1 2022. 69 funds tracked by Wall St. Rank hold PRDS as of Q2 2022.

  • ExodusPoint Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 49,699 Pardes Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $359K.
  • ExodusPoint Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • ExodusPoint Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $359K in Q1 2022.
  • 69 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.